Aptamers and aptazymes: Accelerating small molecule drug discovery

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 5, 2002, Pages 690-700

  Burgstaller, Petra ^a   Jenne, Andreas ^a   Blind, Michael ^a  

^a NascaCell Technologies AG   (Germany)

Author keywords

Aptamer; Aptazyme; High throughput screening; In vitro selection; Intramer; Target validation

Indexed keywords

APTAMER; APTAZYME; COUMAMYCIN A1; CYTOHESIN 1; ENZYME; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; RIBOZYME; RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; COMBINATORIAL CHEMISTRY; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; VIRUS INHIBITION;

ANIMALS; DNA; ENZYMES; GENE TARGETING; HUMANS; LIGANDS; PHARMACOLOGY; PROTEOME;

EID: 0036771047     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Harris S, Foord SM: Transgenic gene knock-outs: Functional genomics and therapeutic target selection. Pharmacogenomics (2000) 1:433-443.
2. Schlingensiepen R, Schlingensiepen KH: Antisense oligodeoxynucleotides - highly specific tools for basic research and pharmacotherapy. In: Antisense - From Technology to Therapy. Schlingensiepen R, Schlingensiepen KH (Eds), Blackwell, Berlin, Germany (1997):3-28.
3. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391:806-811.
4. Sharp PA: RNA interference - 2001. Genes Dev (2001) 15:485-490.
5. Elbashir SM, Lendeckel W, Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 15:188-200. Study describing that the effect of RNAi can be mediated by short double-stranded RNA of oligonucleotides, having a major impact on their use as genetic tools and therapeutics.
6. Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, Schultz J, Rick JM, Michon AM, Cruciat CM, Remor M et at. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 415:141-147. This important paper describes the high-throughput characterization of protein complexes in yeast. The results are a major milestone for the understanding of the four-dimensional, higher-order structure of the proteome.
7. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 346:818-822. In vitro selection processes to isolate aptamers were developed independently in two separate laboratories. This paper, along with reference [8•], describes the basic principles of the in vitro selection of nucleic acid ligands.
8. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 249:505-510. In vitro selection processes to isolate aptamers were developed independently in two separate laboratories. This paper, along with reference [7•], describes the basic principles of the in vitro selection of nucleic acid ligands.
9. Kusser W: Chemically modified nucleic acid aptamers for in vitro selections: Evolving evolution. J Biotechnol (2000) 74:27-38.
10. Brody EN, Gold L: Aptamers as therapeutic and diagnostic agents. J Biotechnol (2000) 74:5-13.
11. Famulok M, Mayer G, Blind M: Nucleic acid aptamers - From selection in vitro to applications in vivo. Acc Chem Research (2000) 33:591-599.
12. Conrad R, Keranen LM, Ellington AD, Newton AC: Isozyme- specific inhibition of protein kinase C by RNA aptamers. J Biol Chem (1994) 269:32051-32054. Study demonstrating the ability of aptamers to specifically discriminate between protein isoforms, which are 96% homologous.
13. Seiwert SD, Stines NT, Aigner S, Ahn NG, Uhlenbeck OC: RNA aptamers as pathway-specific MAP kinase inhibitors. Chem Biol (2000) 7:833-843. Study demonstrating the ability of aptamers to specifically discriminate between MAP kinases and phosphorylated and unphosphorylated forms thereof
14. Kensch O, Connolly BA, Steinhoff HJ, McGregor A, Goody RS, Restle T: HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J Biol Chem (2000) 275:18271-18278.
15. Pagratis NC, Bell C, Chang YF, Jennings S, Fitzwater T, Jellinek D, Dang C: Potent 2′-amino-, and 2′- fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat Biotechnol (1997) 15:68-73.
16. 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem (1998) 273:20556-20567.
17. Cox JC, Rudolph P, Ellington AD: Automated RNA selection. Biotech Prog (1998) 14:845-850.
18. Cox JC, Ellington AD: Automated selection of anti-protein aptamers. Bioorg Med Chem (2001) 9:2525-2531. A pioneering study demonstrating the automation of the in vitro selection process to isolate protein-binding aptamers.
19. Drolet DW, Jenison RD, Smith DE, Pratt D, Hicke BJ: A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX). Comb Chem High Throughput Screen (1999) 2:271-278.
20. Tang J, Breaker RR: Rational design of allosteric ribozymes. Chem Biol (1997) 4:453-459. First report of allosterically regulated ribozymes (aptazymes).
21. Robertson MP, Ellington AD: In vitro selection of an allosteric ribozyme that transduces analytes to amplicons. Nat Biotechnol (1999) 17:62-66. Elegant approach to combine aptazymes and PCR amplification for the detection of small molecules.
22. Breaker RR: Engineered allosteric ribozymes as biosensor components. Curr Opin Biotechnol (2002) 13:31-39. Recent review on aptazyme technology.
23. Jenne A, Hartig JS, Piganeau N, Tauer A, Samarsky DA, Green MR, Davies J, Famulok M: Rapid identification and characterization of hammerhead-ribozyme inhibitors using fluorescence-based technology. Nat Biotechnol (2001) 19:56-61.
24. Piganeau N, Thuillier V, Famulok M: In vitro selection of allosteric ribozymes: Theory and experimental validation. J Mol Biol (2001) 312:1177-1190.
25. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC, Bendele RA: Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res (2000) 17:1503-1510.
26. Ross R: Cell biology of atherosclerosis. Annu Rev Physiol (1995) 57:791-804.
27. Floege J, Johnson RJ: Multiple roles for platelet-derived growth factor in renal disease. Miner Electrolyte Metabol (1995) 21:271-282.
28. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic N: Novel approach to specific growth factor inhibition in vivo: Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol(1999) 154:169-179.
29. Ostendorf T, Kunter U, Van Roeyen C, Dooley S, Janjic N, Ruckman J, Eitner F, Floege J: The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-β system. J Am Soc Nephrol (2002) 13:658-667.
30. Leppänen O, Janjic N, Carlsson MA, Pietras K, Levin M, Vargeese C, Green LS, Bergqvist D, Ostman A, Heldin CH: Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol (2000) 20:E89-E95.
31. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res (2001) 61:2929-2934.
32. Connolly DT: Vascular permeability factor: A unique regulator of blood vessel function. J Cell Biochem (1991) 47:219-223.
33. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 146:1029-1039.
34. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med (1994) 330:1431-1438.
35. Huang J, Moore J, Soffer S, Kim E, Rowe D, Manley CA, O'Toole K, Middlesworth W, Stolar C, Yamashiro D, Kandel J: Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg (2001) 36:357-361.
36. 165 mediates glomerular endothelial repair. J Clin Invest (1999) 104:913-923.
37. Blind M, Kolanus W, Famulok M: Cytoplasmic RNA modulators of an inside-out signal-transduction cascade. Proc Natl Acad Sci USA (1999) 96:3606-3610.
38. Konopka K, Lee NS, Rossi J, Duzgunes N: Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication. Gene (2000) 255:235-244.
39. Good PD, Krikos AJ, Li SX, Bertrand E, Lee NS, Giver L, Ellington A, Zaia JA, Rossi JJ, Engelke DR: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther (1997) 4:45-54.
40. Andreola ML, Pileur F, Calmels C, Ventura M, Tarrago-Litvak L, Toulme JJ, Litvak S: DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry (2001) 40:10087-10094.
41. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G: A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res (1997) 25:2730-2736.
42. Chaloin L, Vidal P, Lory P, Mery J, Lautredou N, Divita G, Heitz F: Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. Biochem Biophys Res Commun (1998) 243:601-608.
43. Konopka K, Duzgunes N, Rossi J, Lee NS: Receptor ligand- facilitated cationic liposome delivery of anti-HIV-1 Revbinding aptamer and ribozyme DNAs. J Drug Targeting (1998) 5:247-259.
44. Yamamoto R, Katahira M, Nishikawa S, Baba T, Taira K, Kumar PK: A novel RNA motif that binds efficiently and specifically to the Tat protein of HIV and inhibits the transactivation by Tat of transcription in vitro and in vivo. Genes Cells (2000) 5:371-388.
45. Joshi P, Prasad VR: Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol (2002) 76:6545-6557.
46. Thomas M, Chedin S, Caries C, Riva M, Famulok M, Sentenac A: Selective targeting and inhibition of yeast RNA polymerase II by RNA aptamers. J Biol Chem (1997) 272:27980-27986.
47. Shi H, Hoffman BE, Lis JT: RNA aptamers as effective protein antagonists in a multicellular organism. Proc Natl Acad Sci USA (1999) 96:10033-10038.
48. Mayer G, Blind M, Nagel W, Bohm T, Knorr T, Jackson CL, Kolanus W, Famulok M: Controlling small guanine-nucleotide-exchange factor function through cytoplasmic RNA intramers. Proc Natl Acad Sci USA (2001) 98:4961-4965. Interesting study on aptamer-based dissection of signal transduction pathways within leukocytes.
49. Kolanus W, Seed B: Integrins and inside-out signal transduction: Converging signals from PKC and PIP3. Curr Opin Cell Biol (1997) 9:725-731.
50. Martell RE, Nevins JR, Sullenger BA: Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Mol Ther (2002) 6:30-34.
51. Ishizaki J, Nevins JR, Sullenger BA: Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nat Med (1996) 2:1386-1389.
52. Sullenger BA, Lee TC, Smith CA, Ungers GE, Gilboa E: Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication. Mol Cell Biol (1990) 10:6512-6523.
53. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E: Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell (1990) 63:601-608.
54. Thompson JD, Ayers DF, Malmstrom TA, McKenzie TL, Ganousis L, Chowrira BM, Couture L, Stinchcomb DT: Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res (1995) 23:2259-2268.
55. Jayasena SD: Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin Chem (1999) 45:1628-1650.
56. Hamaguchi N, Ellington A, Stanton M: Aptamer beacons for the direct detection of proteins. Anal Biochem (2001) 294:126-131.
57. Hyde-DeRuyscher R, Paige LA, Christensen DJ, Hyde-DeRuyscher N, Lim A, Fredericks ZL, Kranz J, Gallant P, Zhang J, Rocklage SM, Fowlkes DM et al. Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries. Chem Biol (2000) 7:17-25.
58. Green LS, Jellinek D, Jenison R, Ostman A, Heldin CH, Janjic N: Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry (1996) 35:14413-14424.
59. Green LS, Bell C, Janjic N: Aptamers as reagents for high-throughput screening. Biotechniques (2001) 30:1094-1096, 1098, 1100.
60. Hartig JS, Najafi-Shoushtan SH, Grüne I, Yan A, Ellington AD, Famulok M: Protein-dependent ribozymes report molecular interactions in real-time. Nat Biotechnol (2002) 20:717-722. This important paper describes for the first time the use of inhibitory aptamers to screen functionally equivalent small molecules. Additionally, various design strategies are disclosed that allow the construction of aptazyme reporters from aptamer sequences.
61. Bartel DP, Zapp ML, Green MR, Szostak JW: HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell (1991) 67:529-536.
62. Giver L, Bartel DP, Zapp ML, Green MR, Ellington AD: Selection and design of high-affinity RNA ligands for HIV-1 Rev. Gene (1993) 137:19-24.
63. Heaphy S, Finch JT, Gait MJ, Kam J, Singh M: Human immunodeficiency virus type 1 regulator of virion expression, rev, forms nucleoprotein filaments after binding to a purine-rich 'bubble located' within the revresponsive region of viral mRNAs. Proc Natl Acad Sci USA (1991) 88:7366-7370.
64. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 355:564-566.
65. Drolet DW, Moon-McDermott L, Romig TS: An enzyme-linked oligonucleotide assay. Nat Biotechnol (1996) 14:1021-1025.
66. Davis KA, Abrams B, Lin Y, Jayasena SD: Use of a high affinity DNA ligand in flow cytometry. Nucleic Acids Res (1996) 24:702-706.
67. Davis KA, Lin Y, Abrams B, Jayasena SD: Staining of cell surface human CD4 with 2′-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucleic Acids Res (1998) 26:3915-3924.
68. Charlton J, Sennello J, Smith D: In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol (1997) 4:809-816.
69. German I, Buchanan DD, Kennedy RT: Aptamers as ligands in affinity probe capillary electrophoresis. Anal Chem (1998) 70:4540-4545.
70. Blank M, Weinschenk T, Priemer M, Schluesener H: Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J Biol Chem (2001) 276:16464-16468.
71. Fredriksson S, Gullberg M, Jarvius J, Olsson C, Pietras K, Gustafsdottir SM, Ostman A, Landegren U: Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol (2002) 20:473-477. The paper describes the design of an assay that combines target recognition of aptamers, enzymatic ligation and PCR, creating one of the most sensitive detection methods reported to date.
72. Famulok M: Bringing picomolar protein detection into proximity. Nat Biotechnol (2002) 20:448-449.
73. Potyrailo RA, Conrad RC, Ellington AD, Hieftje GM: Adapting selected nucleic acid ligands (aptamers) to biosensors. Anal Chem (1998) 70:3419-3425.
74. Jensen KB, Atkinson BL, Willis MC, Koch TH, Gold L: Using in vitro selection to direct the covalent attachment of human immunodeficiency virus type 1 Rev protein to high-affinity RNA ligands. Proc Natl Acad Sci USA (1995) 92:12220-12224.
75. Golden MC, Collins BD, Willis MC, Koch TH: Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J Biotechnol (2000) 81:167-178.
76. NASCACELL GMBH (Blind M, Jenne A, Famulok M, Hartig J, Najafi S): Method for identifying compounds or lead structures against RNA target motifs and RNA/protein interactions. WO-00242491 (2000).